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Background: For patients with critical limb ischemia (CLI), there is a great need for alternative treatment strategies. One
option is therapeutic angiogenesis by administration of vascular growth factors. The lack of convincing clinical data
supporting this strategy may be due to the ignorance of endogenous angiogenic processes in CLI. To evaluate the
importance of vascular growth factors in the pathogenesis in CLI and provide information for clinical growth factor
treatment trials, we determined the levels of vascular endothelial growth factor (VEGF) and fibroblast growth factor 2
(FGF-2) in the ischemic legs of patients with this disease.
Methods: Skin and muscle biopsies from the calf and groin were gathered from 25 patients with CLI. Control samples came
from 10 orthopedic patients and from 5 patients who were undergoing coronary artery bypass. The concentration of
VEGF and FGF-2 in the biopsies was measured by enzyme-linked immunoassay, and to localize growth factor
production, biopsied sections were immunostained.
Results: Patients with CLI had lower levels of VEGF in distal skin samples than in proximal ones (mean difference: 16.7
pg/mg total protein, 95% confidence interval: 1.0 to 32.3, P  .038), but these levels were similar to those in distal
samples from control subjects (8.0,4.6 to 20.5, P .65). In muscle, VEGF concentrations were similar in calf and groin
(5.4,12.4 to 23.1, P .55), but distal levels were higher than in distal samples from control subjects (23.7, 1.2 to 56.7,
P  .028). Skin FGF levels tended to be higher in distal samples (45.3, 26.5 to 117.5, P  .090) and were higher than
in skin from control subjects (106.2,11.4 to 223.8, P .050). Also in muscle, distal samples had higher levels of FGF-2
(35.6,1.6 to 59.7, P .006), but these levels were similar to what was found in control subjects (29.4.,16.3 to 81.2,
P  .39). Growth factors were located in connective tissue between muscle fibers. In skin, the predominant FGF-2
staining was just below the epidermal layer, whereas VEGF appeared in the dermal layer.
Conclusions: The results indicate that there are elevated concentrations of FGF-2 in calf muscle, whereas VEGF
concentrations do not appear to be higher in the ischemic part of the leg in patients with CLI. These findings suggest that
VEGF supplementation may be a more appropriate strategy for therapeutic angiogenesis to the calf area for CLI than
FGF-2. (J Vasc Surg 2004;39:621-8.)
The incidence of critical limb ischemia (CLI) has been
estimated to be 500 to 800 per million inhabitants per
year.1 Of the patients diagnosed, 40% to 60% will undergo
invasive treatment, but for the remainder, the only option is
often amputation, and there is a great need for alternative
treatment strategies. One such option is therapeutic angio-
genesis. It has been attempted for treatment of CLI and
ischemic heart disease in several patient series and in a few
randomized trials. The most common growth factors used
are vascular endothelial growth factor (VEGF) and fibro-
blast growth factor 2 (FGF-2), which both stimulate angio-
genesis in vitro and in animal models of myocardial and
hind limb ischemia.2-4 Unfortunately, the results from the
clinical trials treating coronary artery disease have not
shown a clear effect of treatment.5 One randomized trial for
patients with intermittent claudication has been published
that shows improved peak walking time.6 Mixed results are
reported from nonrandomized patient series. An explana-
tion for the lack of convincing effect in many therapeutic
angiogenesis trials may be that we have limited knowledge
of the complex pathogenesis in ischemic heart disease and
CLI—and particularly the role of endogenous angiogenesis
and arteriogenesis.7-9 Because ischemia-related mecha-
nisms and local inflammation presumably control both
processes, it is possible that they also are of importance for
disease progression. For instance, episodes of rest pain may
involve hypoxia and thus increased expression of VEGF
through HIF-1,10 and ischemia-induced inflammation
may further amplify local VEGF production and other
vascular growth factors such as FGF.11-14 If the concentra-
tion of these growth factors is already elevated in CLI, the
motives for therapeutic angiogenesis can be questioned.
We therefore, to evaluate the importance of vascular
growth factors in the pathogenesis in CLI and provide
information for clinical growth factor treatment trials, de-
termined the levels of VEGF and FGF-2 in the ischemic
legs of 25 patients with CLI. The aim was to evaluate
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whether these levels already are elevated in critically isch-
emic legs.
METHODS
Patients. Patients were recruited at the Vascular Sur-
gical Department at Karolinska Hospital, Stockholm, Swe-
den. A patient was included if he or she met the following
criteria: (1) had stable (4 weeks’ duration) symptoms of
rest pain or ischemic distal ulcers; (2) had objective signs of
distal ischemia—an ankle blood pressure of 60 mm Hg,
toe blood pressure of40 mm Hg, or ankle-brachial index
(ABI) of0.5; and (3) was a candidate for femoropopliteal
bypass below knee or a crural bypass with angiographically
verified superficial femoral artery, popliteal artery, or pro-
funda artery occlusion and one or more patent calf arteries.
Twenty-five consecutive patients who met these criteria
were recruited and underwent revascularization with the
proximal anastomosis in the groin and the distal in the calf,
enabling sampling of skin and muscle tissue in each patient
in approximately the same area. None of the patients had a
medically documented history of cancer or arthritis. Four-
teen were men and 11 were women, with a mean age of
74.0 (57 to 91) years. Fourteen had diabetes (9 men, 5
women). Patients’ characteristics are presented in Table I.
The preoperative arteriogram showed occlusion in the su-
perficial femoral artery in 17 patients (68%); the remaining
patients had more than one significant stenosis of the
superficial femoral artery. Fourteen (56%) of the patients
had occlusion of the popliteal artery, and 1 patient had
occlusion of the profunda artery. The outflow vessels for
the procedures were the popliteal artery below the knee (n
 12), peroneal (n  4), anterior tibial (n  6), and
posterior tibial (n  3). The patients had a mean of 1.4
(range, 1 to 2) vessels patent down to the foot.
Control subjects. Ten patients in the orthopedic
clinic who were suffering from arthrosis and undergoing
hip or knee arthroplasty served as control subjects. Biopsies
were collected from skin and muscle tissue in the proximal
thigh (five patients) and close to the knee (five patients). All
of the hip arthroplasty patients were women with a mean
age of 67 (range, 56 to 74) years, and one of them had
diabetes. The knee arthroplasty patients were three women
and two men with a mean age of 79 (70 to 89) years. One
of them had diabetes. Skin biopsies were also obtained from
the distal leg while harvesting vein from five patients who
were undergoing coronary artery bypass surgery (CABG).
These five CABG patients were men with a mean age of 71
(58 to 83) years. None had diabetes. The control subjects
were screened to exclude patients with a medical history of
peripheral arterial disease or those who demonstrated ob-
jective signs of distal ischemia (ABI of 0.9).
The study was performed according to institutional
guidelines and was approved by the ethics review commit-
tee at Karolinska Hospital. Informed consent was obtained
from each patient and control subject before his or her
inclusion.
Tissue biopsies. Samples were collected during oper-
ation, before heparinization. Skin and muscle biopsies were
obtained from the distal part of the calf incision (musculus
gastrocnemius) and from the groin (musculus quadriceps).
The availability of samples from different muscles depended
on the anatomical prerequisites; for instance, specimens
were also obtained from the soleus (patients 3, 4, 5, and 12)
and sartorius muscles (patients 1, 3, 4, 6, 7, 19, 20, and 22
to 25). In patients 1, 3, 4, 6, 19, 20, 22, 23, and 25, the
only proximal muscle gathered was from sartorius. In pa-
tient 22, the only distal muscle gathered was from the
anterior tibial muscle, and in patient 12, the only distal
muscle was from soleus. In the orthopedic control subjects,
the biopsies were collected from the proximal quadriceps
muscle and from the skin in the proximal lateral thigh or
from the distal medial part of the quadriceps muscle and the
skin medial to the knee. The skin biopsies gathered from
the patients undergoing coronary artery bypass surgery
were gathered in the mid calf. Biopsies were immediately
frozen in pieces of 5  5 mm on dry ice and stored at
70°C. One piece of each sample was placed in 4% para-
formaldehyde with 15% sucrose at pH 7.4 for 4 hours,
followed by 15% sucrose in PBS for 24 hours and then 70%
ethanol before being embedded in paraffin and used for
histology and immunohistochemistry. For protein analysis,
muscle samples were weighed (range, 40 to 60 mg), cut
into small pieces, and homogenized in cell lysis buffer. The
Table I. Patient characteristics.*
Patient
Diabetes
(yes/no)
Ulcer or
gangrene
(yes/no)
ABP
(mm Hg)
TBP
(mm Hg) ABI
1 Y Y 0 10 0
2 Y Y 0 — 0
3 Y Y 160 10 1.6
4 Y N 60 — 0.4
5 Y Y 80 — 0.5
6 N Y 65 — 0.3
7 N N 60 — 0.5
8 Y Y 30 10 0.2
9† N Y 110 — 0.7
10 Y Y 60 — 0.4
11 N Y — 30 0.5
12 Y Y 0 — 0
13 N Y 40 0 0.4
14 N Y 40 — 0.2
15 Y N 40 — 0.2
16 Y Y 100 0 0.6
17 N N 40 — 0.3
18 N Y 90 10 0.6
19 Y Y 40 — 0.3
20 Y N 50 20 0.4
21 N Y 25 — 0.2
22 N N 70 — 0.3
23 Y N 70 — 0.3
24 N N 35 — 0.3
25 Y Y 65 — 0.4
ABP, Ankle blood pressure; TBP, toe blood pressure; ABI, ankle-brachial
index.
*The patients are listed in the same order as in Figure 1.
†The ABP and ABI for this patient were higher than indicated in the
inclusion criteria, and the TBP was not measurable because of toe ulcers.
The patient was included despite this because of gangrene.
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buffer used was modified after Vadiveloo et al.15 One
milliliter of buffer was used for every 40 mg of sample (for
10 mL of buffer: 1000L of 0.5 mol/L Tris, 300L of 5.0
mol/L NaCl, 0.02 g of sodium vanadate, 0.05 g of Na
Deoxycolic acid, 50 L of Triton X-100, 6500 L of
distilled water, 2000 L of 0.5 mol/L NaF, 20 L of 0.1
mol/L Na vanadate, 10 L (10 mg/mL) of aprotinin, 10
L (10 mg/mL) of leupeptin, 20 L of 0.5 mol/L ethyl-
enediaminetetraacetic acid, and 100 L of 0.1 mol/L
phenylmethylsulfonyl fluoride). After homogenization, the
suspension was processed by centrifuge at 3000 g for 10
minutes, and the supernatant was then centrifuged at
12000  g for 10 minutes and stored at 70°C.
Protein determination. The total protein content of
the supernatant was determined by BCA Protein Assay Kit
(Pierce 23225), and the concentrations of total human
VEGF (isoform 121 and 165 combined) and FGF-2 were
determined with an enzyme-linked immunoassay (Quan-
tikine, R & D Systems). Each analysis included standard
solution of VEGF or FGF-2, and all standards and samples
were run in duplicate. Techniques and materials that were
used followed the protocol provided by the manufacturer.
The concentrations of VEGF and FGF-2 were analyzed in
relation to the total protein content in the muscle and skin
samples and were presented in picograms per milligram of
total protein.
Histology. From each paraffin-embedded biopsy, sec-
tions were cut in 5-m sections and placed on glass slides.
The sections were stained (hematoxylin and eosin) and
used for descriptive histology.
Immunohistochemistry. Immunohistochemical stain-
ing was used to localize VEGF and FGF-2 expression in
histological sections. The techniques employed were mod-
ifications of methods described elsewhere.16 Tissue sec-
tions were placed in xylene for 10 minutes and in absolute
ethanol for 5 minutes, rinsed in 95% and 70% ethanol, and
then washed in distilled water. Hydrogen peroxidase (3%
diluted in distilled water) was added for 5 minutes, fol-
lowed by three washes in phosphate-buffered saline (PBS),
for a total of 5 minutes. Blocking solution (2% rabbit serum
in PBS) was applied for 1 hour at room temperature. A goat
anti-FGF basic antibody and a goat polyclonal anti-human
VEGF antibody (both R & D Systems) diluted in 0.1%
bovine serum albumin in PBS were applied to the tissue
sections at a concentration of 2g/mL at4°C overnight.
Incubation was followed by three 5-minute washes in PBS.
A secondary biotinylated rabbit-anti-goat antibody (Vec-
tor) was added in a concentration of 7.5g/mL, for 1 hour
at room temperature. ABC reagent (Vectastatin ABC kit;
Vector) was used according to the manufacturer’s recom-
mendations for 30 minutes at room temperature. DAB
(3,3	-diaminobenzidine) peroxidase substrate kit was used
to localize the immune complexes. The sections were coun-
terstained with hematoxylin and mounted with Mountex.
In this method, the immune complexes appear brown, and
nuclei are blue.
Statistics. Data was analyzed by comparing growth
factor concentrations from the following: (1) distal and
proximal biopsies and (2) between patients and control
subject samples. For muscle, this was done by comparing
growth factor concentrations from gastrocnemius (distal)
to quadriceps or sartorius muscle when the quadriceps was
not available (proximal). For control subjects, the samples
collected from distal skin in patients who were undergoing
knee arthroplasty and coronary bypass surgery were ana-
lyzed together. Results were expressed as mean and range
or SD, and differences, also as 95% confidence intervals of
the difference. Differences were analyzed by the Student t
test and Mann-Whitney U-test. A second analysis was per-
formed by comparing clinical parameters with levels of
growth factors. For all analysis, P.05 was considered to be
statistically significant.
RESULTS
VEGF and FGF-2 concentrations in patients. Lev-
els of VEGF were lower in distal skin compared with
proximal skin (mean difference: 16.7 pg/mg total protein,
95% CI: 1.0 to 32.3, P  .038; Fig 1A). VEGF con-
centrations in muscle samples from the two sites were
similar (5.4, 12.4 to 23.1, P  .55; Table II). FGF-2
concentrations in skin tended to be higher distally (45.3,
26.5 to 117.5, P  .09) and were higher in distal muscle
compared with proximal muscle (35.6, 1.6 to 59.7, P 
.006; Fig 1B).
The concentrations of VEGF and FGF-2 in different
muscles, comparing quadriceps (n  15) to the sartorius
muscle (n  11; comparison, P  .34) and gastrocnemius
(n  23) to soleus muscle (n  4; comparison, P  .34),
were similar (Table II).
VEGF and FGF-2 concentration in control subjects
compared with patients. VEGF values in skin samples
were similar in patients and controls (distal: 8.0, 4.6 to
20.5, P  .65, and proximal: 23.1, 50.3 to 7.8, P 
.19; Fig 2). In distal muscle samples, patients had higher
VEGF concentrations than did controls (23.7, 1.2 to 56.7,
P  .028), whereas proximal samples were similar (13.0,
47.1 to 13.0, P  .29). FGF-2 concentrations in distal
skin samples were higher in patients (106.2, 11.4 to
223.8, P  .050), whereas proximal levels were similar
(31.1,67.8 to 204.6, P .12). In muscle, both proximal
and distal levels were similar (distal: 29.4,16.3 to 81.2, P
 .39, and proximal: 4.9, 11.7 to 29.5, P  .31; Fig 2).
Clinical correlation. No relationship between VEGF
and FGF-2 protein levels in muscle or skin and the patients’
age, ankle blood pressure, or ABI was observed at either
site. Patients with diabetes had similar VEGF levels to those
without the disease, both in proximal and distal skin and
muscle samples. Patients with diabetes had significantly
lower FGF-2 levels in distal muscle samples (68.8, 22.4 to
164.5) than did patients without diabetes (139.8, 52.3 to
267.0; P  .009), but in proximal muscle and in skin,
FGF-2 values were similar. When subdividing the patients
according to presence of ulcers, those with open ulcers or
gangrene had slightly higher VEGF levels in their distal (P
 .053) skin but had no differences in proximal skin or
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muscle samples. Patients with ulcers had similar FGF-2
levels both in skin and muscle as did those without.
Histology and immunohistochemistry. Descriptive
histology showed randomly distributed inflammatory cells
Fig 1. Examples of individual growth factor concentrations in tissue samples from 25 patients with critical limb
ischemia. Skin concentrations of VEGF (A) and muscle concentrations of FGF-2 (B) (proximal samples are missing in
two of the patients).
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in muscle and skin sections in some patients, and no clear
differences were observed comparing distal and proximal
sites. Sections revealed positive staining to both VEGF and
FGF-2 in muscle and skin at both proximal and distal sites.
VEGF as well as FGF-2 was detectable at the muscle fiber
periphery and close to capillaries and inflammatory cells in
connective tissue between muscle bundles and in the der-
mis layer of the skin. Moreover, strong staining in the skin
was observed just below the epidermal layer (Fig 3).
DISCUSSION
The principal observation in this study is that there
were elevated levels of FGF-2 in distal samples. This was
consistent in muscle, both compared with proximal samples
in the patients and with distal sample concentrations in
control subjects. For skin, the values were significantly higher
only for the comparison within each patient. Also, when
compared with control subjects, the FGF-2 concentrations
were around 70% higher but varied greatly. Elevated levels of
FGF-2 in distal tissue are in line with results from animal
models of peripheral ischemia16,17 and with the hypothesis
that ischemia-induced inflammation initiates local growth fac-
tor production. This is because skin ulcers—healed and
open—may contribute to inflammation in the area.
It is plausible that even a chronic disease such as CLI
will have episodes of ischemic insults accentuating inflam-
Table II. Concentrations (mean pg/mg of total protein 
 SD, ELISA) of VEGF and FGF-2 and the number of
samples obtained at each site.
Group Muscle Skin
Distal
gastrocnemius Distal soleus
Proximal
quadriceps
Proximal
sartorius Distal Proximal
CLI patients
VEGF 53.22 
 35.33 73.52 
 46.67 59.20 
 34.93 62.01 
 25.95 30.66 
 18.81 49.20 
 39.67
n  23 n  4 n  15 n  11 n  23 n  23
FGF-2 108.46 
 60.85 102.19 
 23.71 69.07 
 39.36 62.91 
 54.34 343.22 
 170.77 321.62 
 247.25
n  20 n  4 n  15 n  9 n  23 n  24
Control subjects
VEGF 31.40* 
 13.03 73.63 
 24.41 23.18 
 5.80 66.49 
 21.77
n  5‡ n  5 n  10† n  5
FGF-2 75.40 
 61.04 45.15 
 9.42 237.12* 
 92.53 218.53 
 97.13
n  5‡ n  5 n  10† n  5
*P  .05 comparing patient and control subject samples at the same site.
†Samples gathered from patients undergoing coronary bypass surgery and knee arthroplasty.
‡Samples from distal quadriceps muscle gathered from patients undergoing knee arthroplasty.
Fig 2. Mean (SD) concentrations of VEGF and FGF-2 in patient and control samples
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mation and necrosis, thus maintaining FGF-2 production.
FGF-2 has been detected in high levels in serum from
patients with ischemic heart disease18 and is supported by a
study by Rohovsky et al,13 who measured circulating levels
of FGF-2 in a mixed patient population with leg ischemia
and found highly elevated concentrations compared with
those in healthy subjects. The origin of this circulating
FGF-2 could hypothetically be other organs than the
Fig 3. Staining (brown) of distal samples from one patient with CLI (patient 11). A, Negative control skin;
B, anti-VEGF skin; C, anti–FGF-2 skin; D, negative control muscle; E, anti-VEGF muscle; and F, anti–FGF-2 muscle.
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chronically ischemic leg, but our observations indicate that
skeletal muscle and skin in the ischemic leg may be the main
sources of this protein.
Another discovery was the low levels of VEGF in distal
skin. This observation appeared both in patients and con-
trols. That our CLI patients had VEGF levels in the skin in
the same range as control subjects and had only slightly
increased VEGF levels in distal, presumably ischemic mus-
cle, was quite surprising, especially considering our previ-
ously mentioned assumption that episodes of rest pain
involve hypoxia and increased expression of VEGF. The
moderately increased VEGF levels in distal tissue contrast
with findings in most previously described in vitro11,19 and
animal models.12,16 On the contrary, low VEGF concen-
trations in distal skin appear to be the normal state in
humans, and the effect of ischemia on the skin of our
patients was not enough to cause a rise in VEGF produc-
tion. Another explanation is that the tissues in the rather
proximal part of the calf at which the biopsies were ob-
tained did not become ischemic enough to stimulate VEGF
expression.
In distal muscle, our results indicate that there may be
an increase in VEGF concentrations compared with con-
trols, whereas in patients, the concentrations were similar at
distal and proximal sites. This indicates that there may be a
small increase in VEGF expression in ischemic muscle from
our patients. In humans, expression of VEGF has been
shown to be up-regulated, both in infarcted myocardium20
and in normal human skeletal muscle after dynamic exer-
cise.21 The most probable reason for the lack of profound
increase of VEGF in ischemic muscle from our patients is
that there may be a difference in growth factor production
after acute and chronic ischemia. For example, the longest
duration evaluated after arterial ligation in animal models of
hind limb ischemia varies between 21 and 40 days.16,22,23
Interestingly, Hershey et al23 noted normalized tissue lev-
els of VEGF beyond 10 days, indicating that VEGF release
and production is rather a part of an acute ischemic process.
We also analyzed the effect of clinical factors on growth
factor concentration in the biopsies, despite this not being
the primary aim of the study. Even though the low number
of patients included did not make a detailed analysis reli-
able, our breakdown analysis suggests that diabetic disease
may have some impact on the levels of FGF-2 found in the
skeletal muscle. Patients with diabetes had lower levels than
did patients without diabetes, as well as control subjects.
Previous animal studies have demonstrated reduced VEGF
expression in muscle samples from diabetic mice with hind
limb ischemia.24 In human studies, similar25 or elevat-
ed26,27 circulating levels of FGF-2 and VEGF have been
reported in patients with diabetes. Although we could not
demonstrate a relationship to the presence of collateral
vessels to growth factor levels or diabetic disease, the low
levels of FGF-2 found is in agreement with the clinical
observation that patients with diabetes often lack collaterals
from the profunda system.
In line with earlier studies, we located the VEGF and
FGF-2 to the connective tissue surrounding muscle bun-
dles and arterioles in skeletal muscle sections.28 Very little
staining was found within muscle fibers. The proximity to
what we believe are inflammatory cells emphasizes the
relation between inflammation and growth factor produc-
tion.
Besides FGF-2 staining in the connective tissue in the
dermal layer of the skin, the samples also stained strongly
for FGF-2 just under the epidermal layer. This area corre-
sponds to where keratinocytes usually are located. This cell
type is highly active and largely responsible for the high cell
turnover of the superficial cell layers of the skin, as well as a
possible FGF-2 producer.29 Accordingly, the explanation
for the larger production of FGF-2 compared with skeletal
muscle may be due to the contribution of epidermal layer
production. Keratinocytes may also be activated by a local
skin inflammation.
There are limitations to our study. Unfortunately, CLI
represents, despite the attempts made to define a disease
entity, a heterogeneous patient population. It is therefore
possible that we included patients with a wide variety of
disease states and with ischemia that was unevenly distrib-
uted in the legs. Our biopsies may therefore not be repre-
sentative of true ischemic tissue. Slightly varying operative
procedures and preferences of the surgeons made it impos-
sible to get identical samples from all patients and control
subjects. We tried, however, to obtain muscles of similar
fiber types as far as was possible and to obtain skin from the
same location in the calf and groin. The low number of
patients included calls into question the breakdown analy-
ses of clinical factors. We were unfortunately unable to
identify a control group for which samples from the same
muscles in the calf area as in patients could be obtained, and
we therefore used control muscle samples from the knee
region.
In conclusion, we have demonstrated an association
between distal ischemia and elevated levels of FGF-2 in the
calf from patients with CLI. We did not observe an increase
in VEGF concentrations or profoundly enhanced levels in
the ischemic distal samples, indicating that there could be a
relative lack of VEGF in the ischemic part of the leg in
patients with CLI.
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CORRECTION
In: Acute arterial complications associated with total hip and knee arthroplasty (Calligaro KD, Dougherty
MJ, Ryan S, Booth RE. J Vasc Surg 2003;38:1170-7).
On page 1175, in the Conclusion section of this article, the acronym is incorrect. The second sentence states that
acute arterial complications were more frequent with THA [total hip arthroplasty]. The sentence should read, “In this
series these complications were more frequent with TKA [total knee arthroplasty], especially repeat knee operations.”
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